Skip to content

Climb Bio, Inc. CLYM Market capitalization

Market capitalization at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$123.83B-0.2%
Amgen logo
AmgenAMGN
$189.67B+13.3%
Vera Therapeutics logo
Vera TherapeuticsVERA
$2.87B+87.5%
Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
$521.73M+526%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$860.08M+94.2%
Jade Biosciences, Inc. Common Stock logo
Jade Biosciences, Inc. Common StockJBIO
$692.89M

Other financials

Income statement

See full
Operating income-$15.2M+33.9%
Net income-$13.7M+34.0%
EPS (diluted)-$0.20+35.5%

Balance sheet

See full
Cash & equivalents$8.4M-71.2%
Total debt$479.0K+1.1%
Total equity$148.1M-23.4%
Total assets$152.4M-24.1%

Cash flow

See full
Operating cash flow-$14.4M+6.8%
CapEx$109.0K
Free cash flow-$15.6M-183%

Valuation

See full
Enterprise value$717.07M+1,247%

Returns & leverage

See full
Return on equity-30.9%-10.3pp
Debt / equity0.0×
Current ratio27.9×+13.6×

Where this comes from

Computed from the period-end share price: $327.21M.

The official record: Climb Bio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Climb Bio, Inc.'s market capitalization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Climb Bio, Inc.'s market capitalization?
Climb Bio, Inc. (CLYM) reported market capitalization of $327.21M in Q1 2026.
How has Climb Bio, Inc.'s market capitalization changed year-over-year?
Climb Bio, Inc.'s market capitalization increased by 297.5% year-over-year, from $82.32M to $327.21M.
What does market capitalization mean?
The total market value of the company's equity at the quarter end (share price × shares outstanding), sampled from daily market data. The latest point tracks the live price.